Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (61-70 of 740) with videos related to

Pageof 74
Sort By:
Expert Opinion on Emerging Drugs|March 1, 2011
Emerging drugs for Waldenström's macroglobulinemiaEfstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Expert Opinion on Pharmacotherapy|February 22, 2014
Author's reply: To PMID 23705905Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Expert Review of Hematology|July 19, 2016
Managing renal complications in multiple myelomaDespoina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
Expert Review of Hematology|June 25, 2021
Managing complications secondary to Waldenström's macroglobulinemiaIlias Pessach, Meletios A Dimopoulos, Efstathios Kastritis
The New England Journal of Medicine|September 23, 2020
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19Evangelos Terpos, Andreas Mentis, Meletios A Dimopoulos
Current Hematologic Malignancy Reports|September 4, 2012
Prevention and treatment of myeloma bone diseaseEvangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos
Expert Review of Hematology|November 19, 2010
Pathogenesis and management of myeloma bone diseaseDimitrios Christoulas, Evangelos Terpos, Meletios A Dimopoulos
Leukemia Research|May 18, 2010
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myelomaSundar Jagannath, Meletios A Dimopoulos, Sagar Lonial
Hematology/Oncology Clinics of North America|May 21, 2023
Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström MacroglobulinemiaEirini Solia, Meletios A Dimopoulos, Efstathios Kastritis
Blood|January 10, 2022
How I treat relapsed multiple myelomaEfstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Pageof 74

Showing results (61-70 of 740) with videos related to

Sort By:
Pageof 74
Expert Opinion on Emerging Drugs|March 1, 2011
Emerging drugs for Waldenström's macroglobulinemiaEfstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Expert Opinion on Pharmacotherapy|February 22, 2014
Author's reply: To PMID 23705905Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Expert Review of Hematology|July 19, 2016
Managing renal complications in multiple myelomaDespoina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
Expert Review of Hematology|June 25, 2021
Managing complications secondary to Waldenström's macroglobulinemiaIlias Pessach, Meletios A Dimopoulos, Efstathios Kastritis
The New England Journal of Medicine|September 23, 2020
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19Evangelos Terpos, Andreas Mentis, Meletios A Dimopoulos
Current Hematologic Malignancy Reports|September 4, 2012
Prevention and treatment of myeloma bone diseaseEvangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos
Expert Review of Hematology|November 19, 2010
Pathogenesis and management of myeloma bone diseaseDimitrios Christoulas, Evangelos Terpos, Meletios A Dimopoulos
Leukemia Research|May 18, 2010
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myelomaSundar Jagannath, Meletios A Dimopoulos, Sagar Lonial
Hematology/Oncology Clinics of North America|May 21, 2023
Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström MacroglobulinemiaEirini Solia, Meletios A Dimopoulos, Efstathios Kastritis
Blood|January 10, 2022
How I treat relapsed multiple myelomaEfstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Pageof 74